Novartis announced positive data from the FLAME study evaluating the efficacy of the once-daily Ultibro Breezhaler for reducing COPD flare-ups.
In a press release, Dr Kenneth Chapman, director of the Asthma and Airway Centre of the University Health Network in Toronto said the FLAME study proved the ability of Ultibro Breezhaler to reduce flare-ups and underscored the importance of bronchodilators as a foundation for COPD patient care.
“Preventing exacerbations preserves the health and quality of life of patients struggling with COPD. The FLAME study results greatly improve our understanding of COPD management,” Chapman said.
The FLAME clinical trial included 3,362 COPD patients and was conducted in 43 countries. The primary goal of the trial was focused to demonstrate that Ultibro Breezhaler was not inferior to salmeterol/fluticasone in managing COPD exacerbations during a treatment period of 52 weeks. Fluticasone is a glucocorticoid.
Ultibro Breezhaler is a steroid-free, once-daily double bronchodilator approved in more than 40 worldwide.